Floatz Rating
B60/100
Confidence
Indicative
Sponsor
NRG Oncology
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04588246CT.gov Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Digestive System Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Memantine (this asset) | NRG Oncology | P3 | B · 60 |
| Dexasone | Cedars-Sinai Medical Center | P4 | BB |
| Irinotecan | Amgen | P2 | BB |
| Fluorouracilum | Alliance for Clinical Trials in Oncology | P2 | BB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Brian Anderson, MD | P4 | BB |
| Mlf 541 | B. Braun Melsungen AG | P3 | BB |
| Epinephrine | Cedars-Sinai Medical Center | P4 | BB |
| Marcaine | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | P4 | BB |
| Capecitabine | UNICANCER | P2 | B |
+42 more in the Digestive System Cancer cohort
Other indications for Memantine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Alzheimer Disease | — | P4 | BBB · 74 |
| Lewy Body Dementia | — | P4 | BBB · 72 |
| Dementia | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Memantine in Digestive System Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/memantine-digestive-system-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →